Connect with us

Healthcare Buzz

Granules India’s total income increases by 18 percent

Granules India Ltd., announced financial results for its fourth quarter and financial year ended on March 31, 2018. The company’s standalone total income during the year was Rs. 1678 crore. In this year the company recorded EBITDA and PAT were Rs. 317 crore and Rs. 139 crore respectively. The company’s board of directors proposed a final dividend of 25 paise/share of face value of Rs. 1 each.

During the year, there were certain macro and industry developments which did not allow the growth in revenue to reflect in profitability, which is attributable to increased cost of materials. Even as there is uncertainty on when these pressures will abate, the company is working toward enhancing and strengthening infrastructure and product portfolio.

Granules India continues to improve their regulatory compliance framework and completion of USFDA audits at four of their sites in the last financial year validates their position. The company has built capacity and infrastructure to support their business expansion plans and look forward to consolidating the key investments and focus on execution of their strategies.

Copyright © 2024 Medical Buyer

error: Content is protected !!